MX360368B - Regiones de anticuerpo modificado y sus usos. - Google Patents

Regiones de anticuerpo modificado y sus usos.

Info

Publication number
MX360368B
MX360368B MX2014012978A MX2014012978A MX360368B MX 360368 B MX360368 B MX 360368B MX 2014012978 A MX2014012978 A MX 2014012978A MX 2014012978 A MX2014012978 A MX 2014012978A MX 360368 B MX360368 B MX 360368B
Authority
MX
Mexico
Prior art keywords
modified antibody
antibody regions
regions
modified
antibodies
Prior art date
Application number
MX2014012978A
Other languages
English (en)
Other versions
MX2014012978A (es
Inventor
Hwai Wen Chang
Gerhard Frey
Jay M Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of MX2014012978A publication Critical patent/MX2014012978A/es
Publication of MX360368B publication Critical patent/MX360368B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a regiones de Fc modificadas de anticuerpos, y sus usos, tal como en anticuerpos que contienen una región de Fc de la presente invención.
MX2014012978A 2012-04-27 2013-04-26 Regiones de anticuerpo modificado y sus usos. MX360368B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639729P 2012-04-27 2012-04-27
PCT/US2013/038538 WO2013163630A1 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof

Publications (2)

Publication Number Publication Date
MX2014012978A MX2014012978A (es) 2015-02-05
MX360368B true MX360368B (es) 2018-10-29

Family

ID=49483948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012978A MX360368B (es) 2012-04-27 2013-04-26 Regiones de anticuerpo modificado y sus usos.

Country Status (13)

Country Link
US (2) US20150065690A1 (es)
EP (2) EP2841458A4 (es)
JP (1) JP6470170B2 (es)
KR (2) KR20150008082A (es)
CN (1) CN104428317B (es)
AU (3) AU2013251309B2 (es)
BR (1) BR112014026740B1 (es)
CA (1) CA2871807C (es)
HK (1) HK1207654A1 (es)
IN (1) IN2014DN08721A (es)
MX (1) MX360368B (es)
RU (1) RU2014147741A (es)
WO (1) WO2013163630A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2947605A1 (en) * 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2017158426A1 (en) * 2016-03-14 2017-09-21 University Of Oslo Engineered immunoglobulins with altered fcrn binding
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
EP3873940A4 (en) * 2018-10-31 2022-11-30 BioAtla, Inc. ANTI-CTLA4 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF
JP2022524081A (ja) 2019-03-08 2022-04-27 オブシディアン セラピューティクス， インコーポレイテッド 調整可能な制御のためのヒトカルボニックアンヒドラーゼ２組成物及び方法
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021030303A1 (en) 2019-08-12 2021-02-18 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20230183353A1 (en) * 2020-05-21 2023-06-15 Zydus Lifesciences Limited Fc variant and preparation thereof
CN115803091A (zh) 2020-05-22 2023-03-14 福迈康股份公司 Ace2-fc融合蛋白及其用途
WO2022090469A2 (en) 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof
AU2022230745A1 (en) 2021-03-03 2023-08-17 Formycon Ag Formulations of ace2 fc fusion proteins
WO2023094507A1 (en) 2021-11-24 2023-06-01 Formycon Ag Improved ace2 fusion proteins
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003286467B2 (en) * 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004041854A2 (en) 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
JP2006524039A (ja) * 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
EP1697415A1 (en) * 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
DK1817340T3 (da) * 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
DK1919503T3 (en) * 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
EP1943332A4 (en) * 2005-10-14 2011-04-13 Medimmune Inc CELLULAR DISPLAY OF ANTIBODY LIBRARIES
ES2532461T3 (es) * 2007-12-26 2015-03-27 Xencor, Inc. Variantes de FC con enlazamiento alterado a FCRN
ES2675730T3 (es) 2008-06-04 2018-07-12 Macrogenics, Inc. Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
PL2975051T3 (pl) 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
CA2807014A1 (en) * 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8483058B2 (en) 2010-08-17 2013-07-09 Qualcomm Incorporated Systems and methods for traffic policing
WO2013010927A1 (en) 2011-07-15 2013-01-24 Basell Poliolefine Italia S.R.L. Polyolefin strap comprising a random copolymer of propylene with 1-hexene
CA3186007A1 (en) * 2011-09-30 2013-04-04 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
JP2015506687A (ja) * 2012-01-19 2015-03-05 セラピューティック プロテインズ インターナショナル， エルエルシー 抗−ｃｄ２０抗体リツキシマブの安定化

Also Published As

Publication number Publication date
EP2841458A4 (en) 2015-09-16
US20150065690A1 (en) 2015-03-05
US10954288B2 (en) 2021-03-23
CA2871807A1 (en) 2013-10-31
AU2013251309B2 (en) 2017-06-22
MX2014012978A (es) 2015-02-05
CN104428317B (zh) 2018-08-28
JP6470170B2 (ja) 2019-02-13
KR20200037434A (ko) 2020-04-08
US20180186863A1 (en) 2018-07-05
IN2014DN08721A (es) 2015-05-22
JP2015515497A (ja) 2015-05-28
AU2019202229B2 (en) 2021-02-11
AU2017225111A1 (en) 2017-09-28
BR112014026740A2 (pt) 2017-06-27
RU2014147741A (ru) 2016-06-20
BR112014026740A8 (pt) 2021-06-15
BR112014026740B1 (pt) 2022-10-04
KR20150008082A (ko) 2015-01-21
EP2841458A1 (en) 2015-03-04
EP3470433A1 (en) 2019-04-17
AU2019202229A1 (en) 2019-04-18
HK1207654A1 (en) 2016-02-05
CA2871807C (en) 2022-10-04
AU2017225111B2 (en) 2019-01-03
AU2013251309A1 (en) 2014-10-30
CN104428317A (zh) 2015-03-18
WO2013163630A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
NZ739622A (en) Antibodies to tau
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
IN2014DN09417A (es)
TN2012000366A1 (en) Anticoagulant antidotes
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
IN2014DN05885A (es)
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
TN2013000388A1 (en) Anticoagulant antidotes
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
NZ743971A (en) Antibodies to tau
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration